Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 21, 2004. The report primarily details changes in directors' interests in the company's Ordinary Shares and announces a share repurchase transaction.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data points disclosed are related to share transactions:
- Share Repurchase Price: 1,195.06 pence per share.
- US Retirement Fund ADR Price: Average price of $41.66.
- Treasury Shares Held: 45,423,000 shares (post-repurchase).
- Shares in Issue: 5,889,460,975 shares (excluding Treasury shares).
Material Changes
The filing reports the following material changes regarding equity and director interests:
- Share Repurchase: On September 20, 2004, the company purchased 825,000 Ordinary shares for Treasury under authority granted at the May 17, 2004 Annual General Meeting.
- US Retirement Plan Adjustment: On September 16, 2004, the GlaxoSmithKline US Retirement Savings Plan's holding of Ordinary Share ADRs decreased from 19,181,782 to 19,113,637 due to fund movements.
- Employee Trust Corrections and Distributions:
- 6,175 Ordinary Shares were transferred to the GlaxoSmithKline Employee Trust (GSK Trust) on September 15, 2004, to rectify an incorrect distribution to Belgian Performance Share Plan participants.
- 34,172 Ordinary Shares were transferred from the GSK Trust to participants in the SmithKline Beecham Employee Share Option Plan 1991 on September 17, 2004.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural disclosure regarding equity movements and director interests.
Key Facts for Investor Verification
- Verify the total cost of the 825,000 share repurchase (825,000 shares x 1,195.06 pence).
- Confirm the updated total number of shares in issue (5,889,460,975) and treasury holdings (45,423,000) in subsequent filings.
- Note that Directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe have potential interests in the GSK Trust and US Retirement Plan shares as beneficiaries.
- Recognize that this filing does not contain operational or financial performance data for the period.